SCLC患者-话题@MedSci - williamhill asia

#SCLC患者#

174篇内容 | 2162人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2069087, encodeId=357e206908edd, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期, objectType=article, longId=737804, objectId=dbf0e37804ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbf0e37804ff, replyNumber=0, likeNumber=73, createdTime=2023-06-14, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbf0e37804ff, moduleTitle=Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dbf0e37804ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069083, encodeId=e0922069083dc, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, objectType=article, longId=728275, objectId=a347e2827567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a347e2827567, replyNumber=0, likeNumber=62, createdTime=2022-09-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a347e2827567, moduleTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a347e2827567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069081, encodeId=b0482069081d6, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法, objectType=article, longId=727709, objectId=f4e9e2770970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4e9e2770970, replyNumber=0, likeNumber=73, createdTime=2023-03-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4e9e2770970, moduleTitle=J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f4e9e2770970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069078, encodeId=0ab820690e80a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, objectType=article, longId=727665, objectId=42bae2766592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42bae2766592, replyNumber=0, likeNumber=68, createdTime=2022-08-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42bae2766592, moduleTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=42bae2766592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069077, encodeId=797720690e7e9, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, objectType=article, longId=727473, objectId=6721e274735c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6721e274735c, replyNumber=0, likeNumber=107, createdTime=2023-03-16, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6721e274735c, moduleTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6721e274735c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069070, encodeId=6aaa20690e00a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Radiology：术前脑MRI分期对IA期无症状NSCLC患者预后没有影响, objectType=article, longId=301235, objectId=97f9301235f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97f9301235f7, replyNumber=0, likeNumber=76, createdTime=2022-05-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97f9301235f7, moduleTitle=Radiology：术前脑MRI分期对IA期无症状NSCLC患者预后没有影响, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=97f9301235f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069076, encodeId=57d220690e650, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=AACR重磅之GLORY试验：SCC244对携带MET 14外显子跳变（METex14）的NSCLC患者的II期研究, objectType=article, longId=723990, objectId=9450e23990da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9450e23990da, replyNumber=0, likeNumber=77, createdTime=2022-09-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9450e23990da, moduleTitle=AACR重磅之GLORY试验：SCC244对携带MET 14外显子跳变（METex14）的NSCLC患者的II期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9450e23990da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069082, encodeId=7ba620690828f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=2022 ASCO：YAP-1对ES-SCLC患者免疫治疗疗效的预测价值, objectType=article, longId=728254, objectId=ce42e2825488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce42e2825488, replyNumber=0, likeNumber=83, createdTime=2023-03-21, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce42e2825488, moduleTitle=2022 ASCO：YAP-1对ES-SCLC患者免疫治疗疗效的预测价值, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ce42e2825488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069072, encodeId=bacf20690e212, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=67, createdTime=2022-05-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069079, encodeId=b56d20690e9fb, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异, objectType=article, longId=727693, objectId=a4d6e2769330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4d6e2769330, replyNumber=0, likeNumber=70, createdTime=2022-12-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4d6e2769330, moduleTitle=Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a4d6e2769330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069085, encodeId=defc206908540, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗, objectType=article, longId=727759, objectId=e5e5e27759c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5e5e27759c4, replyNumber=0, likeNumber=70, createdTime=2023-04-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5e5e27759c4, moduleTitle=J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e5e5e27759c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069060, encodeId=baf920690605a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, objectType=article, longId=295111, objectId=e91429511199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e91429511199, replyNumber=0, likeNumber=60, createdTime=2022-10-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e91429511199, moduleTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e91429511199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069058, encodeId=fca4206905811, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, objectType=article, longId=294238, objectId=ea07294238cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea07294238cf, replyNumber=0, likeNumber=104, createdTime=2022-12-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea07294238cf, moduleTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ea07294238cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069080, encodeId=9e1f206908005, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=53, createdTime=2023-03-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069049, encodeId=8f08206904931, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, objectType=article, longId=221572, objectId=bfd12215e24f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfd12215e24f, replyNumber=0, likeNumber=62, createdTime=2022-02-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfd12215e24f, moduleTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bfd12215e24f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069086, encodeId=e3ea20690866f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, objectType=article, longId=727467, objectId=fe0ae2746739, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe0ae2746739, replyNumber=0, likeNumber=62, createdTime=2023-02-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe0ae2746739, moduleTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fe0ae2746739)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069084, encodeId=819e20690844f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, objectType=article, longId=728900, objectId=2d14e28900af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d14e28900af, replyNumber=0, likeNumber=66, createdTime=2023-01-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d14e28900af, moduleTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2d14e28900af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069043, encodeId=f2d52069043fd, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比, objectType=article, longId=220998, objectId=36ac220998de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ac220998de, replyNumber=0, likeNumber=85, createdTime=2022-10-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ac220998de, moduleTitle=Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=36ac220998de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069038, encodeId=9857206903814, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, objectType=article, longId=220334, objectId=0e9e2203349a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e9e2203349a, replyNumber=0, likeNumber=0, createdTime=2022-03-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e9e2203349a, moduleTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0e9e2203349a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069066, encodeId=a2ad206906693, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后, objectType=article, longId=295592, objectId=e4e3295592aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e3295592aa, replyNumber=0, likeNumber=63, createdTime=2022-02-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e3295592aa, moduleTitle=Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e4e3295592aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

SCLC患者

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期

2023-06-14

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素

2022-09-22

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法

2023-03-18

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效

2022-08-10

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS

2023-03-16

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Radiology：术前脑MRI分期对IA期无症状NSCLC患者预后没有影响

2022-05-03

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

AACR重磅之GLORY试验：SCC244对携带MET 14外显子跳变（METex14）的NSCLC患者的II期研究

2022-09-12

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

2022 ASCO：YAP-1对ES-SCLC患者免疫治疗疗效的预测价值

2023-03-21

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-05-23

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异

2022-12-28

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗

2023-04-10

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%

2022-10-15

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效

2022-12-09

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2023-03-05

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效

2022-02-11

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效

2023-02-22

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较

2023-01-13

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比

2022-10-07

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性

2022-03-04

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后

2022-02-24

科室
- - 订阅+
  - 更多科室
工具
服务